Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Dec 2025

Kanwar Nisha, Seyi Abidoye B, Tan Nelly, Rojas Carlos, Ernani Vinicius, Rumilla Kandelaria M, Borad Mitesh J, Zheng Gang

Abstract excerpt

Circulating tumor DNA (ctDNA) testing is a minimally invasive alternative to tissue biopsy and is ideal for inaccessible tumors or limited samples. It captures tumor heterogeneity over time and different anatomic locations, unlike the static snapshot provided by a biopsy. In this report, we describe a 68-year-old female with an initial diagnosis of metastatic pancreatic adenocarcinoma (a pancreas head mass with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Circulating Tumor DNA

Share to Clinical Decision-Making

Share to Indoles

Share to Pancreatic Neoplasms

Share to Pyrimidines

Source

Identifiers

PMID: 41671451
DOI: 10.6004/jnccn.2025.7098

Genes

EGFR
CDKN2A
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.PMID 41671451Read ↗

Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas.Semantic proximity Read ↗

Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancerSemantic proximity Read ↗

Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.Semantic proximity Read ↗

Liquid Biopsy Using Ascites and Pleural Effusion Supernatant for Genomic Profiling in Gastrointestinal and Lung CancersSemantic proximity Read ↗

Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test.Semantic proximity Read ↗

Targeted deep sequencing helps distinguish independent primary tumors from intrapulmonary metastasis for lung cancer diagnosis.Semantic proximity Read ↗

The significance of using liquid biopsy to improve treatment outcomes for metastatic patientsSemantic proximity Read ↗

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.Semantic proximity Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.Semantic proximity Read ↗

State of the Art of Pathologic and Molecular Testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.